Published in Ann Pharmacother on September 24, 1992
Orthopedic complications of overweight in children and adolescents. Pediatrics (2006) 2.25
Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes (2011) 1.32
Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol (2002) 1.32
Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab (2004) 0.96
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. HIV Med (2013) 0.88
Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. Health Qual Life Outcomes (2014) 0.81
Artificial neural networks: opening the black box. Cancer (2001) 2.00
New hemodialysis membranes and vancomycin clearance. Am J Health Syst Pharm (1995) 1.40
Recombinant interleukin-2: a biological response modifier. Clin Pharm (1991) 1.40
Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy (2000) 1.39
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2011) 1.21
Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med (1997) 1.07
Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med (1995) 1.06
Computed tomographic analysis of brain morphometrics in 30 healthy men, aged 21 to 81 years. Ann Neurol (1985) 1.02
Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy (1997) 1.02
Human infection with herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment. Pharmacotherapy (1988) 0.99
Treatment of suspected postcholecystectomy diarrhea with psyllium hydrophilic mucilloid. Clin Pharm (1990) 0.94
A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol (1999) 0.93
Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol (2000) 0.93
Stability of sodium ampicillin in aqueous solutions. Am J Hosp Pharm (1972) 0.91
Computer-assisted categorization of brain computerized tomography pixels into cerebrospinal fluid, white matter, and gray matter. Comput Biomed Res (1985) 0.89
Quantitation of flupirtine and its active acetylated metabolite by reversed-phase high-performance liquid chromatography using fluorometric detection. J Chromatogr (1984) 0.88
Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid (1993) 0.87
Prevalence-value-accuracy plots: a new method for comparing diagnostic tests based on misclassification costs. Clin Chem (1999) 0.85
Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab (2001) 0.84
Stability of solutions of essential amino acids. Am J Hosp Pharm (1973) 0.84
Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol (2000) 0.84
Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol (2000) 0.84
Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. Biopharm Drug Dispos (1983) 0.83
Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab (2001) 0.83
A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol (1999) 0.83
Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm (1981) 0.82
Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet (1981) 0.81
Stability of cisplatin in aqueous solution. Am J Hosp Pharm (1979) 0.81
Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Ann Pharmacother (2001) 0.81
Use of herbal therapies by adults seen in an ambulatory care research setting: an exploratory survey. J Altern Complement Med (2000) 0.80
Bosentan and the endothelin system in congestive heart failure. Clin Cardiol (2000) 0.79
Levothyroxine replacement therapy in central hypothyroidism: a practice report. Pharmacotherapy (1999) 0.79
Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Pharmacotherapy (2001) 0.79
Disposal of antineoplastic wastes at the National Institutes of Health. Am J Hosp Pharm (1984) 0.79
Human gene therapy. Clin Pharm (1993) 0.79
The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. Pharmacotherapy (1999) 0.78
The interdisciplinary team's approach to lupus nephritis. Lupus (1998) 0.78
Pimozide-induced depression in men who stutter. J Clin Psychiatry (1997) 0.78
Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore) (2000) 0.78
Safety reporting in clinical trials. JAMA (2001) 0.78
Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. J Clin Endocrinol Metab (2001) 0.78
Thermal and photolytic decomposition of methotrexate in aqueous solutions. J Pharm Sci (1978) 0.77
Kinetics of chlorambucil hydrolysis using high-pressure liquid chromatography. J Pharm Sci (1982) 0.77
Evaluation of creatinine clearance estimation in an elderly male population. Pharmacotherapy (1988) 0.77
Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis. Ann Pharmacother (1996) 0.77
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health Syst Pharm (1999) 0.77
Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacotherapy (1989) 0.77
Patient-interactive computer system for obtaining medication histories. Am J Hosp Pharm (1993) 0.77
Effects of restricting levothyroxine dosage strength availability. Pharmacotherapy (1997) 0.77
What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features? Brain (1996) 0.76
Treatment options for a patient experiencing pruritic rash associated with transdermal testosterone: a review of the literature. Pharmacotherapy (2001) 0.76
Chemical destruction and disposal of antineoplastic drugs. Am J Hosp Pharm (1986) 0.76
Effects of metformin on energy intake and satiety in obese children. Diabetes Obes Metab (2015) 0.75
A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency. Panminerva Med (2014) 0.75
Mechanism of hydrolysis of halogenated nitrosoureas. J Pharm Sci (1978) 0.75
Zidovudine-associated myopathy. Am J Hosp Pharm (1994) 0.75
Stabilization of 5-azacytidine by nucleophilic addition of bisulfite ion. J Pharm Sci (1979) 0.75
The development and use of an intravenous preparation of allopurinol. Am J Med Sci (1968) 0.75
High-pressure liquid chromatographic analysis of methotrexate in presence of its degradation products. J Pharm Sci (1977) 0.75
Visual compatibility of zidovudine with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm (1988) 0.75
Thermal stability of a long-acting analogue of luteinizing hormone releasing hormone (D-trp6-pro9-NEt-LHRH). Contraception (1983) 0.75
Stability of sodium oxacillin in intravenous solutions. Am J Hosp Pharm (1975) 0.75
Evaluating the potential hazard of handling antineoplastic drugs. Am J Hosp Pharm (1982) 0.75
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemother Rep (1972) 0.75
Evaluation of antineoplastic drug package inserts from different countries. Ann Pharmacother (1996) 0.75
Medical audio response telecommunication information network. Int J Biomed Comput (1972) 0.75
Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. Arch Intern Med (1994) 0.75
Quantitative analysis and alkaline stability studies of allopurinol. J Pharm Sci (1968) 0.75
Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection. Am J Hosp Pharm (1991) 0.75
Dialogues with hospital pharmacists. Curr Concepts Hosp Pharm Manage (1984) 0.75
Maintenance of sterility in freeze-drying of drugs. Am J Hosp Pharm (1968) 0.75
Growth hormone as an adjunct to parenteral nutrition. Am J Hosp Pharm (1994) 0.75
Intravenous additive service improves I.V. preparation. Hospitals (1968) 0.75
Stability of antibiotics in parenteral solutions. Am J Hosp Pharm (1969) 0.75
Sequential comparative hybridizations analyzed by computerized image processing can identify and quantitate regulated RNAs. DNA (1983) 0.75
Quantitation of testolactone and 4,5-dihydrotestolactone in plasma and urine using high-performance liquid chromatography. J Chromatogr (1983) 0.75
Hematuria and crystalluria after high-dose 6-mercaptopurine administration. N Engl J Med (1972) 0.75
Effects of simulated facility-design changes on outpatient pharmacy efficiency. Am J Hosp Pharm (1988) 0.75
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: evaluation of three methods. Am J Health Syst Pharm (1995) 0.75
Formulation and evaluation of ethiodized oil emulsion for intravenous hepatography. J Pharm Sci (1979) 0.75
Role of the hospital pharmacist in the operation of a life island. Am J Hosp Pharm (1968) 0.75
Purity of various methotrexate samples. Cancer Treat Rep (1978) 0.75
Degradation of antiflammin 2 in aqueous solution. J Pharm Sci (1994) 0.75
Surveillance of nosocomial infections by antibiotic monitoring. JAMA (1979) 0.75
Identification and quantitation of impurities in methotrexate. J Pharm Sci (1978) 0.75
Erythromycin, motilin, and gastroparesis. Clin Pharm (1992) 0.75
Control of investigation drugs in a research hospital. Am J Hosp Pharm (1974) 0.75
AIDS facts for pharmacists. Am J Hosp Pharm (1988) 0.75
Long-term stability of aqueous solutions of luteinizing hormone-releasing hormone assessed by an in vitro bioassay and liquid chromatography. J Pharm Sci (1984) 0.75
Automated therapeutic drug monitoring in an ambulatory care endocrine clinic. Ann Pharmacother (1992) 0.75
Particles in parenteral solutions. Arch Pathol (1973) 0.75
Quantitative analysis and stability of 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide in acidic aqueous solutions. J Pharm Sci (1970) 0.75
Stability studies of drugs used in intravenous solutions. I. Am J Hosp Pharm (1967) 0.75
Increased levothyroxine requirements presenting as "inappropriate" TSH secretion syndrome in a patient with nephrotic syndrome. J Endocrinol Invest (2000) 0.75
Stability of methicillin solutions. N Engl J Med (1972) 0.75
Pharmaceutical development: new concept in pharmacy service. Hospitals (1967) 0.75
Sublingual use of benzodiazepines. Drug Intell Clin Pharm (1985) 0.75
Stability of concentrated trimethoprim-sulfamethoxazole admixtures. Am J Hosp Pharm (1989) 0.75